Subproject for Sorafenib for Hepatopulmonary Syndrome

Project: Research project

Project Details

Description

This study is being conducted to determine whether sorafenib may be effective at treating hepatopulmonary syndrome (HPS) compared to placebo.

Primary Aim:
1. To determine whether sorafenib affects alveolar-arterial oxygen gradient (AaPO2) at 12 weeks in patients with HPS

Secondary Aims:
2. To determine whether sorafenib affects intrapulmonary shunting at 12 weeks
3. To determine whether sorafenib affects hematopoietic progenitor cell (HPC) and other biomarker levels at 8 and 12 weeks
4. To determine whether sorafenib affects SF-36 questionnaire scores and Mahler dyspnea index at 8 and 12 weeks
5. To determine whether sorafenib affects the distance walked in six minutes at 8 and 12 weeks
6. To determine whether sorafenib affects AaPO2 and PaO2 at 8 and 12 weeks in patients with HPS
7. To determine whether sorafenib affects oxygen saturation from pulse oximetry at 8 and 12 weeks in patients with HPS
8. To determine whether sorafenib affects functional class at 8 and 12 weeks
9. To determine the safety and side effects associated with sorafenib administration in patients with HPS
StatusFinished
Effective start/end date7/1/1512/31/17

Funding

  • University of Pennsylvania (SUB#567266//5UM1HL116886-03)
  • National Heart, Lung, and Blood Institute (SUB#567266//5UM1HL116886-03)

Fingerprint Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.